cd437

CD437 is a **synthetic retinoid-like small molecule** that functions primarily as a **selective retinoic acid receptor gamma (RARγ) agonist**, but also acts independently of RARγ. It induces **cell cycle arrest and apoptosis in a variety of cancer cell lines** including ovarian, lung, leukemia, breast, and squamous cell carcinoma. Its pro-apoptotic activity is selective for cancer over normal cells, which primarily undergo reversible cell cycle arrest. CD437's mechanism includes **direct inhibition of DNA polymerase alpha (POLA1)**, the enzyme responsible for initiating DNA replication during S-phase, triggering S-phase dependent cytotoxicity in cancer cells. This dual mechanism—RARγ agonism and POLA1 inhibition—underpins its anti-tumor potential. While its bioavailability and pharmaceutical use are under preclinical investigation, CD437 is notable as a lead compound for cancer therapeutics, especially given its selective toxicity to malignant cells and lack of induction of apoptosis in normal cells[1][4][5].

Other names

AHPN6-(4-hydroxy-3-adamantylphenyl)-2-naphthalenecarboxylic acid